IO Biotech recently concluded a phase 3 trial for their experimental cancer vaccine, Cylembio, in combination with Merck’s Keytruda for advanced melanoma. While the trial did not meet its primary endpoint, patients receiving the combination therapy showed an improvement in progression-free survival, with a 23% reduction in the risk of disease progression or death. Particularly promising results were seen in patients with PD-L1 negative tumors and those who had not received prior anti-PD-1 treatment.
The safety profile of Cylembio was favorable, with injection site reactions being the most common side effect. Despite missing the primary endpoint, the trial results support the potential of Cylembio as a treatment option for advanced melanoma patients, with a trend towards improved overall survival. IO Biotech plans to discuss the data with the FDA this fall to determine the next steps for a potential biologics license application submission.
In a separate trial, a genetically engineered herpes simplex virus type 1 (HSV-1), RPI, in combination with Opdivo, showed promising results for patients with advanced melanoma. One-third of patients had their tumors shrink by at least 30%, and nearly one out of six patients had tumors completely disappear. The combination therapy demonstrated a favorable safety profile with mostly grade 1/2 adverse events and broad immune activation associated with response.
The IGNYTE trial, which enrolled 140 patients with advanced melanoma that did not respond or stopped responding to immunotherapy, highlighted the potential of RPI to directly kill tumors and stimulate the body’s immune response. Researchers theorized that Opdivo could enhance the effect of RP1 by leveraging the body’s own immune system to fight cancer cells. The trial results showed significant tumor shrinkage and promising overall survival rates.
A phase 3 trial, IGNYTE-3, is currently ongoing to confirm the findings of the IGNYTE trial, with expectations to enroll over 400 patients. Additionally, a separate trial is assessing RP1 in other non-melanoma skin cancers. These trials represent significant advancements in melanoma treatment, offering hope to patients who have limited treatment options and have not responded to existing therapies.
Key Takeaways:
– IO Biotech’s Cylembio in combination with Keytruda showed promising results for advanced melanoma patients, despite not meeting the primary endpoint.
– The RPI and Opdivo combination therapy demonstrated significant tumor shrinkage and promising overall survival rates in patients with advanced melanoma.
– Ongoing trials, such as IGNYTE-3, aim to confirm the findings of the initial trials and further explore the potential of these innovative treatment approaches in melanoma and other skin cancers.
Tags: immunotherapy, biotech
Read more on managedhealthcareexecutive.com